Levels of Triglycerides and HDL-C in ACS Patients
Evaluation of Triglycerides and HDL-C Levels in Patients With Acute Coronary Syndrome and Normal LDL-C Level
1 other identifier
observational
120
1 country
2
Brief Summary
Background Changes in high-density lipoprotein cholesterol and triglyceride levels have been linked to residual cardiovascular risk, whereas non-high density lipoprotein levels have been shown to be more predictive of cardiovascular risk than are low-density lipoprotein cholesterol levels. We aimed to investigate the impact of high density lipoproteins, triglyceride, and non-high density lipoproteins levels on acute coronary syndrome risk with on-target low density lipoproteins levels.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2018
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 6, 2018
CompletedFirst Posted
Study publicly available on registry
February 12, 2018
CompletedStudy Start
First participant enrolled
June 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2020
CompletedMay 10, 2019
May 1, 2019
1 year
February 6, 2018
May 9, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Decrease ACS events
ACS and Dyslipidemia
1 year
Study Arms (2)
Patients
ACS Lipogram
Controls
Normal LDL-C level Lipogram
Interventions
Eligibility Criteria
Patients with a first or subsequent ACS will be enrolled in our study, who are admitted to CCU of Assiut university hospital and Sohag cardiac \& digestive system center, more over patients should have LDL-C level below 130mg/dl and lipid samples should be obtained within 4 days of admission. They also should receive treatment according to ACS guidelines. Patients and control group data will be collected during a year . Patients will be subjected to: -Full History taking including : History of chest pain or dysnpea History of renal or liver diseases History of drug abuse History of diabetes and hypertension Family history of cardiovascular diseases and dyslipidemia Assessment of risk factors: smoking, alcohol intake, physical inactivity and poor quality diet. Patient Examination : Full general and cardiac examination including : Xanthelasma Body mass index Waist circumference
You may qualify if:
- ACS
- Normal LDL-C
- Not on statin therapy
You may not qualify if:
- Liver disease
- Drug abuse
- End stage renal disease
- Nephrotic syndrome
- Drug abuse
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Assiut university hospital
Asyut, Egypt
Sohag Cardiac and Digestive System Center
Sohag, Egypt
Related Publications (1)
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267-78. doi: 10.1016/S0140-6736(05)67394-1. Epub 2005 Sep 27.
PMID: 16214597RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
February 6, 2018
First Posted
February 12, 2018
Study Start
June 1, 2018
Primary Completion
June 1, 2019
Study Completion
June 1, 2020
Last Updated
May 10, 2019
Record last verified: 2019-05